Figure 5
DC vaccinations in mouse colon cancer model. CT-26 cells (5 × 105/mouse) were injected subcutaneously into the on the right flank of BALB/c mice. (A) Tumor-bearing mice were vaccinated subcutaneously on day 3, 7, 11 and 15 with PBS (○), NK cells (●), pulsed-DCLPS (Δ), pulsed-DCNK+LPS (□) and pulsed-DCNK+LPS+IL-2 (◆). The mice vaccinated with DCLPS, DCNK+LPS, and DCNK+LPS+IL-2 significantly inhibited the tumor growths compared to NK cells and PBS control (*, P < 0.05 on day 15, 21, and 29). The DCNK+LPS+IL-2 group showed the highest inhibition of tumor growth with a significant prolonged survival rate (C). Each vaccination group was evaluated for survival rate. Experiments consisted of 10 mice per group. (B) Tumor-bearing mice in combination therapy group (DCNK+LPS+IL-2 + CPM) were intraperitoneally treated with 50 mg/kg of cyclophosphamide (CPM) on day 6 and then vaccinated subcutaneously with DCs on day 9, 13, 17 and 21. PBS group (○), cyclophosphamide alone (□), pulsed-DCNK+LPS+IL-2 (◆), and DCNK+LPS+IL-2 + CPM (■) were used for vaccination. Combination therapy of DCNK+LPS+IL-2 vaccine with low dose of cyclophosphamide resulted in markedly inhibited tumor growth (*, P < 0.05 on days 35 and 40) and prolonged survival rate (D). Each vaccination group was evaluated for survival rate every 3-4 days. Experiments consisted of 7 mice per group.
